loading
Akari Therapeutics Plc Adr stock is traded at $1.12, with a volume of 9,926. It is up +1.82% in the last 24 hours and down -3.45% over the past month. Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
See More
Previous Close:
$1.10
Open:
$1.1
24h Volume:
9,926
Relative Volume:
0.42
Market Cap:
$36.04M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-3.2175
EPS:
-0.3481
Net Cash Flow:
-
1W Performance:
-0.88%
1M Performance:
-3.45%
6M Performance:
-3.26%
1Y Performance:
-71.95%
1-Day Range:
Value
$1.10
$1.12
1-Week Range:
Value
$1.10
$1.15
52-Week Range:
Value
$0.85
$4.40

Akari Therapeutics Plc Adr Stock (AKTX) Company Profile

Name
Name
Akari Therapeutics Plc Adr
Name
Phone
(646) 350-0702
Name
Address
22 BOSTON WHARF ROAD, BOSTON
Name
Employee
12
Name
Twitter
@AkariTX
Name
Next Earnings Date
2024-04-29
Name
Latest SEC Filings
Name
AKTX's Discussions on Twitter

Compare AKTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.12 35.39M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-18-25 Initiated Maxim Group Buy
Jan-04-19 Upgrade B. Riley FBR Neutral → Buy
Feb-08-18 Initiated B. Riley FBR, Inc. Neutral
Sep-22-17 Upgrade William Blair Mkt Perform → Outperform
May-31-17 Upgrade Chardan Capital Markets Sell → Neutral
Apr-17-17 Reiterated Chardan Capital Markets Sell
Jul-11-16 Initiated Chardan Capital Markets Sell
View All

Akari Therapeutics Plc Adr Stock (AKTX) Latest News

pulisher
Jul 23, 2025

Akari Therapeutics advances cancer-fighting ADC technology with PH1 payload - Investing.com

Jul 23, 2025
pulisher
Jul 23, 2025

Revolutionary Cancer Drug PH1 Targets KRAS, BRAF While Activating Immune System Against Tumors - Stock Titan

Jul 23, 2025
pulisher
Jul 22, 2025

Akari Therapeutics CEO Shares Exclusive Insights on Next-Gen Cancer Drug Development Strategy - Stock Titan

Jul 22, 2025
pulisher
Jul 11, 2025

INKT Stock Quote Price and Forecast - CNN

Jul 11, 2025
pulisher
Jul 01, 2025

Akari Therapeutics shareholders approve equity plan increase and director elections - Investing.com

Jul 01, 2025
pulisher
Jun 25, 2025

Akari Therapeutics Expands Global IP Portfolio: Key Patent Win for Cancer Drug Platform in India - Stock Titan

Jun 25, 2025
pulisher
Jun 24, 2025

AKTX CEO buys 10,000 ADS at $1.20 in Form 4 insider filing - Stock Titan

Jun 24, 2025
pulisher
Jun 18, 2025

Akari Therapeutics secures Indian patent for cancer drug payload - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Akari's Revolutionary Cancer Drug Technology Wins Key Patent in India's 2.08M Patient Market - Stock Titan

Jun 18, 2025
pulisher
May 22, 2025

Akari Therapeutics CEO Reveals Latest Oncology ADC Developments at Major Webull Investor Event - Stock Titan

May 22, 2025
pulisher
May 17, 2025

Akari Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 17, 2025
pulisher
May 01, 2025

Akari Therapeutics appoints new head of oncology business By Investing.com - Investing.com India

May 01, 2025
pulisher
May 01, 2025

Akari Therapeutics appoints new head of oncology business - Investing.com

May 01, 2025
pulisher
Apr 22, 2025

Akari Therapeutics' New CEO Reveals Future Roadmap: Key Insights from First Leadership Address - Stock Titan

Apr 22, 2025
pulisher
Apr 17, 2025

Akari Therapeutics Advances ADC Development Amid Financial Challenges - TipRanks

Apr 17, 2025
pulisher
Apr 16, 2025

Akari Therapeutics Transforms: Next-Gen Cancer Drug Shows Promise Amid 2024 Results - Stock Titan

Apr 16, 2025
pulisher
Mar 20, 2025

Akari Therapeutics names new CEO to drive cancer drug innovation - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Akari Therapeutics names new CEO to drive cancer drug innovation By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Ibotta Inc (IBTA) Shares Soar Above 1-Year High - The News Heater

Mar 20, 2025
pulisher
Mar 20, 2025

Akari Therapeutics Appoints New CEO, Current CEO to Step Down By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Akari Therapeutics Appoints New CEO, Current CEO to Step Down - Investing.com

Mar 20, 2025
pulisher
Mar 03, 2025

Akari Therapeutics secures $7.6 million in private placement - Investing.com India

Mar 03, 2025
pulisher
Feb 25, 2025

Acciones de Alibaba (BABA) caen tras medidas de Trump para frenar inversiones chinas en tecnología - Yahoo Finanzas

Feb 25, 2025
pulisher
Feb 03, 2025

Major ADC Developer Akari Opens Direct Channel to Investors Through Webull Platform - StockTitan

Feb 03, 2025
pulisher
Dec 18, 2024

Akari Therapeutics appoints new CEO and board member - Investing.com

Dec 18, 2024
pulisher
Dec 16, 2024

Akari Therapeutics Strengthens Leadership: Former CFO Returns After $50M Fundraising Success - StockTitan

Dec 16, 2024
pulisher
Nov 19, 2024

Akari Therapeutics Regains Nasdaq Compliance, Secures Market Listing Status - StockTitan

Nov 19, 2024
pulisher
Nov 14, 2024

Akari Therapeutics Completes Peak Bio Merger, Secures $53.2M in Financing Commitments - StockTitan

Nov 14, 2024
pulisher
Oct 05, 2024

Akari Therapeutics Plc faces Nasdaq delisting over equity shortfall - Investing.com India

Oct 05, 2024
pulisher
Jun 19, 2024

Riesgos y oportunidades sobre el futuro de la cotización de YPF - Yahoo Finanzas

Jun 19, 2024
pulisher
Dec 15, 2023

Bancolombia inicia programa para aumentar la liquidez de sus acciones - Yahoo Finanzas

Dec 15, 2023
pulisher
Apr 11, 2023

Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology - StockTitan

Apr 11, 2023
pulisher
Mar 01, 2023

Trending UK-Based Penny Stock Picks 2024 - timothysykes.com

Mar 01, 2023
pulisher
Nov 04, 2022

Peak Bio (PKBO) Stock Price, News & Analysis - MarketBeat

Nov 04, 2022
pulisher
Sep 29, 2022

Las 100 empresas latinoamericanas que se han lanzado a conquistar Wall Street - Yahoo Finanzas

Sep 29, 2022
pulisher
Jan 20, 2021

The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Yahoo Finance

Jan 20, 2021
pulisher
Sep 15, 2020

AKTXAkari Therapeutics plc ADR (0.01 USD) Latest Stock News & Market Updates - StockTitan

Sep 15, 2020
pulisher
Jan 02, 2017

Akari Therapeutics PLC Stock Price Today | NASDAQ: AKTX Live - Investing.com

Jan 02, 2017
pulisher
Aug 18, 2016

Angion Biomedica (ANGN) Stock Price, News & Analysis - MarketBeat

Aug 18, 2016
pulisher
Jul 27, 2011

ADVFN | Live Stock, Options & Crypto Market Data, Trading Tools & Community - ADVFN

Jul 27, 2011

Akari Therapeutics Plc Adr Stock (AKTX) Financials Data

There is no financial data for Akari Therapeutics Plc Adr (AKTX). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Akari Therapeutics Plc Adr Stock (AKTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Gaslightwala Abizer
President & CEO
Jun 23 '25
Buy
1.15
943
1,084
272,371
Gaslightwala Abizer
President & CEO
Jun 20 '25
Buy
1.20
10,000
12,000
271,428
Gaslightwala Abizer
President & CEO
Jun 17 '25
Buy
1.20
15,000
18,000
261,428
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):